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Abstract
Artificially enforced expression of CD80 (B7-1) and CD86
(B7-2) on tumor cells renders them more immunogenic by
triggering the CD28 receptor on T cells. The enigma is that
such B7s interact with much higher affinity with CTLA-4
(CD152), an inhibitory receptor expressed by activated T cells.
We show that unmutated CD80 is spontaneously expressed at
low levels by mouse colon carcinoma cell lines and other
transplantable tumor cell lines of various tissue origins.
Silencing of CD80 by interfering RNA led to loss of
tumorigenicity of CT26 colon carcinoma in immunocompe-
tent mice, but not in immunodeficient Rag/ mice. CT26
tumor cells bind CTLA-4Ig, but much more faintly with a
similar CD28Ig chimeric protein, thus providing an explana-
tion for the dominant inhibitory effects on tumor immunity
displayed by CD80 at that expression level. Interestingly,
CD80-negative tumor cell lines such as MC38 colon carcinoma
and B16 melanoma express CD80 at dim levels during in vivo
growth in syngeneic mice. Therefore, low CD80 surface
expression seems to give an advantage to cancer cells against
the immune system. Our findings are similar with the
inhibitory role described for the dim CD80 expression on
immature dendritic cells, providing an explanation for the low
levels of CD80 expression described in various human
malignancies. (Cancer Res 2006; 66(4): 2442-50)
Introduction
CD80 (B7-1) is a surface glycoprotein shown to increase the
immunogenicity of tumor cell lines when its gene is transfected
into them (1, 2). As a consequence, in tumor grafting experiments,
CD80 transfectants are rejected in syngeneic hosts causing
protective and therapeutic immunity against untransfected tumor
cells, provided that they bear antigen determinants available for
CTL recognition (3). Tumor cell transfection with the CD80 close
relative CD86 (B7-2) also conferred increased immunogenicity to
transplanted tumors with only subtle differences with CD80 (4, 5).
CD80 and CD86 molecules share their ligands on T cells (6–8).
The T-lymphocyte surface molecules CD28 and CTLA-4 (CD152)
bind to them, although with a conspicuously higher affinity in the
case of CTLA-4 (100- to 1,000-fold higher; refs. 9, 10). CD28 is
constitutively expressed on the membrane of resting T lymphocytes
(6), whereas CTLA-4 expression is induced on stimulation (6) and
retained in internal cell compartments (11). Upon T cell receptor
engagement, CTLA-4 molecules are selectively directed to emerge
at the immunologic synapse (11, 12). It has been also observed that
when T cells meet a dendritic cell presenting cognate antigen,
surface CD28 goes to the lipid raft–rich central synapse (13). After
the engagement of ligands, CD28 induces signaling cascades that
enhance proliferation, intensify cytokine secretion, up-regulate
antiapoptotic genes (14), and fuel metabolism for lymphoblast
transformation (15). In fact, CD28’s key role as a costimulatory
molecule has been shown in CD28/ mice, in which both cellular
and T cell–dependent humoral immunity are deficient in a certain
degree (16).
On the contrary, CTLA-4 delivers a signal that decreases T cell
activation by the recruitment of tyrosine (17, 18) and serine/
threonine phosphatases (19). In fact, the function of CTLA-4 is
inhibitory for T cell activation as illustrated in vivo by the
uncontrolled lymphoproliferative/autoimmune syndrome observed
in CTLA-4/ mice (20, 21). Recent genetic evidence using
CD80/ dendritic cells strongly converge to suggest that the low
level of surface CD80 expressed by immature (steady state)
dendritic cells is involved in down-regulating the immune
response (22, 23), by means of its interaction with CTLA-4
(24, 25). In contrast, some published observations have suggested
that CD80 engagement on tumor cells by CTLA-4 would lead to a
better T cell–mediated destruction of malignant cells in certain
mouse models (26, 27), whereas other authors sustain that
B7-CTLA-4 interactions may shield target tumor cells against
CTL-mediated destruction (28). The reason(s) for this set of
discrepant results are unclear.
Nonetheless, the inhibitory function of CTLA-4 against tumor
immunity is best illustrated by the potent immunotherapeutic
effect of monoclonal antibodies (mAb) that interfere with the
function of CTLA-4 (29) in such a way that they induce tumor
rejection in a number rodent tumors (30) with the potential to
induce autoimmunity (31). Interestingly, anti-CTLA-4 antibodies
have been tested in early trials with patients suffering from
melanoma and ovarian cancer, showing evidence of certain clinical
efficacy and unwanted autoimmunity as a side effect (32, 33).
Other members of the CD28/CTLA-4 family, such as PD-1 and
BTLA have also been described to mediate inhibitory effects for the
activation of the lymphocytes on which they are expressed,
suggesting a common theme in the regulation of immune
responses (34, 35). Furthermore, other members of the B7 family
such as B7-H1 and B7-H4 have been shown to inhibit T-cell
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activation (34, 36, 37). In the case of B7-H1, various mouse and
human tumors express the molecule as a tumor escape mechanism
(38), that if interfered with using blocking antibodies, fosters
immunotherapy (39).
The expression of low levels of CD80 and CD86 has been
detected on an important fraction of human melanomas (40, 41),
myelomas (42), and acute myeloid leukemias (43). Moreover, low
levels of expression of CD80 and CD86 detected by RT-PCR and
surface staining has been reported in a series of cell lines derived
from human carcinomas including some of colorectal origin (44).
Interestingly, expression of CD86 was found to be associated with
poor prognosis of leukemia and myeloma (42, 43). However, the
mechanism underlying these clinical observations remains un-
known.
In this study, we found CD80 surface expression at relatively low
levels in various colon carcinoma cells that are widely used as
cancer therapy models upon grafting onto immunocompetent
syngeneic mice, as well as in other mouse malignant cell lines. We
carried out experiments in immunocompetent versus immunode-
ficient mice to assess the relative immunogenicity displayed by
carcinoma cells that express CD80 spontaneously, or the same cell
lines transfected either to specifically silence or to overexpress
CD80. Our results suggest that a low level of CD80 expression
confers an advantage for tumor growth, thus helping to avoid
tumor rejection, whereas high-level CD80 induces immune-
mediated tumor regression.
Materials and Methods
Mice and cells. BALB/c, athymic nude, and C57BL/6 mice were obtained
from Harlan (Barcelona, Spain) and were used between 7 and 14 weeks of
age. A breeding pair of Rag2/ in BALB/c background mice was purchased
from Harlan and bred in our animal facility under pathogen-free conditions.
All animal handling and laboratory procedures were approved by the
institutional animal facility ethical committee and are in accordance with
Spanish regulations.
Five murine colon adenocarcinoma cell lines were used. Three of BALB/c
origin (CT26, C26, and C51) and two of C57BL/6 origin (MC38 and C38). C51
and MC38 cells were transfected with a previously described recombinant
retrovirus expressing murine b7-1 gene (3, 45). Transfections were done by
incubating supernatant of the packaging c-2 lines in the presence of
polybrene as previously described (46). B7+-transfected cells were positively-
selected by immunofluorescence-activated cell sorting (using an EPICS-C,
Coulter, Fullerton, CA) and drug selection as previously described (3).
Transfectants were routinely cultured in the presence of selecting drug.
Cell lines were cultured at 37jC in 5% CO2 in DMEM with 2 mmol/L
L-glutamine, 100 units/mL streptomycin, 100 Ag/mL penicillin and
supplemented with 10% heat-inactivated fetal bovine serum. All cell culture
reagents were from Life Technologies (Basel, Switzerland). For transfectant
selection, hygromycin and puromycin were from Sigma-Aldrich (Madrid,
Spain) and geneticin from Life Technologies. RENCA (renal cell carcinoma)
and B16OVA melanoma were a kind gift from Dr. Allan Melcher (Leeds,
United Kingdom), Lewis lung carcinoma was obtained through Dr. Lea
Eisenbach (Rehovot, Israel), BNL (hepatocellular carcinoma) was obtained
from Dr. Cheng Qian (Pamplona. Spain), and HOPC (myeloma) was
obtained through the American Type Culture Collection (Manassas, VA).
Dr. Paola Ricciardi-Castagnoli kindly provided us with the D1 dendritic cell
line cultured as previously described (47). A cell line from a spontaneous
T cell lymphoma arising from a peripheral lymph node of an elderly C57BL/
6 mouse has been derived in our laboratory.5
CD11c+ splenic cells were purified (>98%) with immunomagnetic beads
from Miltenyi Biotech (Gladsbach, Germany) according to manufacturer-
recommended procedures in an Automacs instrument. Dendritic
cell maturation was induced with 24 hours of culture in the presence of
10 Ag/mL of lipopolysaccharide (Sigma-Aldrich).
Tumor model and in vivo experiments. For assessment of the
tumorigenicity of the CT26 cell line, 5  105 cells were injected s.c. in the
right flank of BALB/c, Rag2/, and athymic nude mice. Similarly, 5  105
MC38 and MC38-B7 cells were injected into C57BL/6 mice. Tumor growth
was monitored weekly by measuring two perpendicular diameters using a
Vernier caliper. Tumor explants were obtained after animal sacrifice by
grinding a minced fragment of solid tumor and plating it in 24-well plates.
Immunofluorescence and flow cytometry. Cells were washed and
labeled with FITC rat anti-mouse CD80 (BD PharMingen, San Diego, CA) for
30 minutes at 4jC. Unbound mAb was removed by washing twice with ice-
cold PBS and immunostaining was determined by flow-cytometry
(FACScalibur, Becton Dickinson, San Jose, CA). An isotype-matched FITC-
tagged mAb was used as a negative control. CD28Ig and CTLA-4Ig were
purchased from R&D (Abingdon, United Kingdom) and used in indirect
immunofluorescence staining with the appropriate FITC-tagged secondary
antibody purchased from Caltag (Burlingame, CA). Anti-CD45 mAb (BD
PharMingen) was used to gate out myeloid-derived cells in cell suspensions
of explanted tumors.
Northern blot and probe preparation. Total cellular RNA was
extracted by the guanidineisothiocyanate technique, run in 20 Ag aliquots
on 1.0% agarose-formaldehyde gel, transferred onto nylon membrane
(Hybond-N; Amersham, United Kingdom) by Northern blot. Blots were
hybridized with the HpaI-XhoI fragment of pLmB7-1SH plasmid, containing
the murine B7-1 cDNA and labeled with 32P-dCTP by means of Multiprime
kit from Amersham.
Cloning and sequencing of murine CD80. Tumor RNA was extracted
by ULTRASPEC-II RNA isolation system (Biotecx, Houston, TX) and
cDNA obtained by reverse transcription using random primers. A DNA
fragment encoding the open reading frame of murine B7-1 was amplified
by PCR using the primers: 5VCCCCATCATGTTCTCCAAAGC3V, 5VACTAAA-
GGAAGACGGTCTGTTCA3V. Another pair of primers was used for B7-1
detection as described (48). In this series of PCRs, the antisense primer was
located in exon 3, which is spliced off to generate a B7-1a molecule.
Therefore, these primers only amplified mCD80 cDNA but not B7-1a cDNA.
PCR products were analyzed by 1% agarose gel electrophoresis and DNA
bands were isolated using Concert Rapid Gel Extraction System (Life
Technologies, Eggestein-Leopoldshafen, Germany) and TA-cloned into
pcDNA3.1/V5-His-TOPO (Invitrogen, Groningen, the Netherlands). Ten
clones were selected and plasmids were isolated using QIAprep Spin
Miniprep Kit (Qiagen, Hilden, Germany) and fully sequenced (ABI PRISM
310 Genetic Analyzer, Applied Biosystems, Foster City, CA).
Gene silencing of CD80. pMSCVpuro (Clontech, Mountain View, CA)
was modified to accommodate the small interfering RNA (siRNA)
expression cassette by sequential digestion and religation of BglII and
HindIII sites (all restriction enzymes were from New England Biolabs,
Ipswich, MA). The expression cassette of pSUPER (49) was extracted by
EcoRI-XhoI digestion and directionally cloned into the modified retroviral
plasmid to yield pMSCV3SUPER. The target sites for CD80 siRNA were
selected using the criteria proposed by Tuschl et al. (50). Three target
sites were selected, and the following oligonucleotides (ordered from
Sigma-Genosys, Cambridge, United Kingdom) were phosphorylated and
cloned into the HindIII-BglII sites of pMSCV3SUPER. Sequences of the
primers synthesized were ( from 5V to 3V): 273+, GAT CCC CAC ATG ACA
AAG TGG TGC TGT TCA AGA GAC AGC ACC ACT TTG TCA TGT TTT
TTG GAA A; 273, AGC TTT TCC AAA AAA CAT GAC AAA GTG GTG CTG
TCT CTT GAA CAG CAC CAC TTT GTC ATG TGG G; 424+, GAT CCC CAA
GAA GGA AAG AGG AAC GTT TCA AGA GAA CGT TCC TCT TTC CTT
CTT TTT TTG GAA A; 424, AGC TTT TCC AAA AAA AGA AGG AAA GAG
GAA CGT TCT CTT GAA ACG TTC CTC TTT CCT TCT TGG G; scr+, GAT
CCC CCT ACA GTA ACT CCG TCA CTT TCA AGA GAA GTG ACG GAG
TTA CTG TAG TTT TTG GAA A; scr, AGC TTT TCC AAA AAC TAC AGT
AAC TCC GTC ACT TCT CTT GAA AGT GAC GGA GTT ACT GTA GGG G.5 Arina et al., unpublished data.
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Plasmids were transfected into CT26 cells by using a 22-kDa linear
polyethylenimine from Polyplus Transfection (Illkirch, France) as described
(51). Twenty-four hours posttransfection, the medium was removed, cells
were washed and fed with fresh medium containing 8 Ag/mL of Puromycin
(Sigma-Aldrich). Stable transfectants were picked 10 days later and
subcultured for analysis.
Results
Constitutive expression of CD80 on murine tumor cell lines.
We assessed CD80 expression in CT26, C26, C51, and MC38 murine
colon carcinoma cell lines by immunofluorescence and flow-
cytometry analysis. To this end, we used a FITC-conjugated
monoclonal antibody specific for murine CD80 (Fig. 1). CT26 and
C26 expressed mouse CD80 (mCD80) at similar dim levels, whereas
mCD80 was almost undetectable on C51 cells and was consistently
undetectable on MC38 cells, thus indicating that CD80 expression
is not a constant feature in murine colon cancer. As shown in
Fig. 1, anti-CD80 mAb also stained the surface of Lewis lung
carcinoma, RENCA (renal cell carcinoma), BNL (hepatocellular
carcinoma), HOPC (multiple myeloma), and a spontaneous T cell
lymphoma cell line derived from C57BL/6 mice that has been
recently derived in our laboratory from a peripheral lymph node.5
These data indicate that the low level of expression of CD80 is not
an exclusive property of colon cancer but is a feature shared by
many types of transplantable mouse malignancies, including MB49
bladder carcinoma and PANC02 pancreatic carcinoma (data not
shown). However, there exist clear exceptions because cultured
B16 melanoma and MC38 colon carcinoma cells do not express
surface CD80 (Fig. 1).
Northern blot analysis of RNA isolated from these colon
cancer cell lines readily showed the presence of two bands (3.9
and 2.2 kb) when using a mCD80-specific probe. These two
bands correspond with the previously reported splicing alter-
natives of the cd80 gene and were also detected on RNA from
lipopolysaccharide-stimulated splenocytes or IFN-g-stimulated
macrophages (Fig. 2A).
cDNA was synthesized from colon carcinoma cell lines using
random primers revealed that CD80 has two variants arising by
alternative splicing that are expressed on the plasma membrane,
one with IgV (membrane distal) + IgC (membrane proximal)
domains, whereas the other contains only the IgV domain (B7-1a;
ref. 52). Both isoforms have similar ligand-binding properties that
map to the IgV domain. Therefore, two different PCRs were done.
One was used for mCD80 mRNA detection with a sense primer
located in the IgV-like domain whereas the antisense primer is
located in the IgC-like domain. The IgC-like fragment of the CD80
protein is encoded by exon 3 which is spliced off to generate B7-1a
molecule (IgV-only isoform). Accordingly, these primers only
amplified mCD80 cDNA but not B7-1a cDNA. As a control, these
primers amplified a similar band from RNA isolated from murine
bone marrow–derived dendritic cells (Fig. 2B). A second series of
PCRs were done in which another pair of primers were used to
amplify cDNA encoding the whole mCD80 open reading frame. In
this PCR, the two alternative splicing variants were found to coexist
in CT26 (Fig. 2B).
Full-length CD80 cDNA was TA-cloned in pCDNA3.1 in order to
verify its sequence. The sequence of at least two independent
clones from CT26 total cDNA was identical to the one published.
The shorter alternative splicing isoform (B7-1a; ref. 53) was also
cloned and sequenced without finding any change when compared
with the published sequence (data not shown). These experiments
conclude that the unmutated, wild-type, and alternative splicing
forms of the cd80 gene are expressed on three murine colon
carcinoma cell lines widely used in tumor immunology experi-
ments on transplantation to syngeneic mice.
Selective binding of CTLA-4 by spontaneously expressed
CD80 on CT26 colon cancer cells. CT26 cells were brightly
Figure 1. Surface expression of CD80 on transplantable tumor cell lines. CD80
surface levels assessed by direct immunofluorescence and FACS analysis on
CT26, C26, and C51 murine colon carcinomas cell lines, on a spontaneous
T-cell lymphoma cell line recently established, on Lewis lung carcinoma (LLC),
RENCA (renal cell carcinoma), BNL (hepatocellular carcinoma), and HOPC
(myeloma). Expression was not detected on the surface of MC38 (colon
carcinoma) and B16-OVA cells (melanoma).
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stained at the cell surface by chimeric proteins containing the
extracellular portion of CTLA-4 and an immunoglobulin tail,
indicating that the tumor molecule was functional at least for
binding this inhibitory ligand (Fig. 3A). However, a similar
chimeric protein containing the extracellular domains of CD28
barely bind CT26 cells even at 100 Ag/mL, whereas readily
stained MC38 cells that had been retrovirally transfected to
stably express high levels of CD80 (Fig. 3B). These data indicate
that CD80 at the levels displayed by CT26 cell shows selective
binding for the inhibitory receptor CTLA-4 if compared with
CD28. The CD80 levels on CT26 resemble those detected on
immature dendritic cells, represented in Fig. 3C by the D1
immortalized dendritic cell line that also preferentially binds
CTLA-4Ig. By contrast, splenic mature dendritic cells express
high levels of CD80 that bind both CTLA-4Ig and CD28Ig
(Fig. 3D). Our observations on tumor cells echo those by
other authors that strongly suggest a role in immune
down-regulation for low, but not completely negative, levels
of CD80 and CD86 expression on immature dendritic cells
(23–25).
Transfection of cd80 gene into colon cancer cells results in
increased immunogenicity and tumor rejection. MC38 is
another mouse colon carcinoma cell line that is negative for
CD80 surface expression by fluorescence-activated cell sorting
Figure 2. Expression of CD80-encoding RNA in murine cultured colon
carcinoma cell lines. A, Northern blot analysis of CD80 mRNA expression on
RNA samples isolated from CT26, C26, C51, and MC38 cell lines, as well as
from splenocytes activated with lipopolysaccharide and from macrophages
treated with rIFN-g. RNAs were transferred onto nylon membranes and
hybridized with a 32P-labeled probe specific for CD80 mRNA. The gel stained
with 18S rRNAs is provided as a control of total RNA load per lane (B )
RT-PCR analysis of CD80 expression. cDNAs were obtained by reverse
transcription and a series of two PCRs were done. In one series, we used a pair
of primers which amplified only full-length CD80 because one of the primers was
located in exon 3, which is spliced off when generating B7-1a mRNA. In these
PCRs, CD80 cDNA was found in CT26 and in a B7-transfected cell line
(MC38-B7), whereas no amplification was obtained from MC38 cDNA. We used
RNA obtained from dendritic cells as a positive control. The second series of
PCRs with the indicated oligos amplified both splicing alternative isoforms
of CD80.
Figure 3. Selective binding of CTLA-4 to CD80 as spontaneously expressed by
CT26 colon cancer cells resembles selective binding of CTLA-4 to immature
dendritic cells. FACS analyses of CT26 cells (A), MC38 cells transfected with
recombinant retrovirus to express high levels of CD80 (B), the immature D1
dendritic cell line (C ), and lipopolysaccharide-matured CD11c+ dendritic cells
(D ). Cells were stained with FITC-tagged anti-CD80 mAb or with CTLA-4Ig
or CD28Ig followed by antihuman Ig-FITC by indirect immunofluorescence.
Analysis of CD11c+ immature spleen cells rendered comparable results to those
in D1 cells (data not shown).
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(FACS) analysis (Fig. 1 and corresponding histograms in Fig. 3B).
These cells were retrovirally modified to express high levels
of CD80 protein on their surface. After pharmacologic selection of
stable transfectants, CD80high cells were selected and cloned by
FACS-assisted sorting. Mock-transfected MC38 and mCD80-
transfected cells (MC38-B7) were s.c. injected into the right flank
of C57BL/6 mice. MC38 cells grafted as lethal tumors in all injected
mice. In contrast, MC38-B7 displayed only transient growth in
syngeneic mice that was constantly followed by complete tumor
regression (Fig. 4A). This is in agreement with an extensive series of
published experiments showing that artificial B7-1 expression, at
least at high levels, increases tumor immunogenicity (1) and also
causes tumor rejection in experimental colon carcinomas (2).
We also transfected the mcd80 gene into the C51 cell line that
expresses very low but detectable levels of endogenous CD80
(Fig. 1). Two cloned transfectants were generated, which are clearly
different in gradual levels of CD80 expression (Fig. 4B). S.c.
injection of such transfected cells into BALB/c mice showed that
the transfected tumors had longer latency than the mock-
transfected C51 in accordance with the levels of CD80 expression
on plasma membrane (Fig. 4C). Indeed, in 50% of the cases,
the brightest expression of CD80 avoided tumor grafting. These
experiments indicated that the intensity of CD80 expression on
transfected cells inversely correlated with tumor progression, but
did not tell whether the low spontaneous level of CD80 had any
biological function.
Silencing of CD80 expression in CT26 results in lack of
tumorigenicity. To study the role of CD80 endogenous expression
in the ability of CT26 colon carcinoma to graft as progressive
tumors, stable transfectants were generated to express siRNAs
targeted to different regions of the CD80’s mRNA in order to silence
its expression. For this purpose, we cloned the pSUPER expression
cassette (49) into retroviral plasmid pMSCV3puro, and in this new
vector, we cloned a hairpin encoding oligonucleotides that would
yield siRNA directed to CD80 mRNA (Fig. 5A). As a control, we
used a scrambled sequence of roughly the same GC content as the
other siRNAs. Puromycin-selected stable transfectants from two
different RNAi constructions were cultured and cloned under
limiting dilutions. Expression of CD80 in two different clones and
in bulk culture cells transfected with an irrelevant scrambled
sequence as a control is shown in Fig. 5B .
The experiments on in vivo growth of each silenced or control
transfectant in normal BALB/c and Rag-2/ are shown in Fig. 5B .
Transfectants in which CD80 expression at the protein level were
highly decreased, lost their capacity to graft as terminal tumors
in immunocompetent mice, but preserved tumorigenicity in
immunodeficient hosts of identical genetic background. Differ-
ences were not attributable to changes in MHC class I levels of
expression because CD80-silenced cells express almost identical
levels of H2-Kd when compared with CT26 wild-type (data not
shown). In addition, when those BALB/c mice who had rejected
CD80-silenced CT26 tumors were rechallenged 3 months later with
unmodified CT26 cells, those tumors were rejected in all mice,
indicating that the mice had been immunized by exposure to
CD80-silenced tumor cells (data not shown). As a whole, these data
indicate that CT26 tumor cells silenced for CD80 expression elicit
stronger antitumor immune responses.
Moreover, one of the repeated culture passages of the clone
424 2.6 spontaneously gave rise to a variant that homogeneously
regained CD80 expression in spite of keeping resistance to
puromycin (Supplementary Fig. S1A). This cell line progressed in
immunocompetent mice indicating that the revertant regaining
CD80 expression has an advantage against the antitumor immune
response. In addition, if these revertant cells were preincubated
Figure 4. Increased immunogenicity of cells
expressing high levels of CD80. A, comparative
study of s.c. tumor development of CD80-negative
MC38 cells and a retrovirally transfected MC38
clone selected for high stable expression of
mCD80. Cells (5  105) from each one of these two
cell lines were injected s.c. in the right flank of two
groups of syngeneic C57BL/6 mice. Levels of
expression of CD80 in transfected or untransfected
cells are provided in accompanying histograms.
B, gradual levels of expression in stable
transfectants of the cd80 gene generated with
recombinant retrovirus in the C51 colon carcinoma
cell line as detected by immunofluorescence with
anti-CD80 mAb (C ). Sequential analysis of the
fraction of BALB/c mice (n = 7 per group)
developing lethal tumors after being injected s.c.
with C51 wild-type colon cancer cells expressing
dim levels of surface CD80 or with cloned variants
that had been transfected with a retrovirus
encoding an expression cassette of CD80. These
variants were selected for bearing different levels
of stable and gradually brighter expression of
CD80 (shown in B).
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and coinjected with 100 Ag/mL of an anti-CD80 blocking antibody,
those tumors were completely rejected in three out of six cases,
whereas all tumors injected with control antibody progressed in
another group of immunocompetent BALB/c mice (Supplementary
Fig. S1B). These data further reinforce the notion that CD80 is the
molecule involved in the escape mechanism and helps to rule out
the possibility that the effects of the silencing could be explained
by clonally variable immunogenicity among CT26 cells. In this
regard, an independently generated polyclonal silenced variant of
CT26 cells transfected with the 424 siRNA construction was also
rejected in four out of six cases in immunocompetent mice,
whereas it progressed in every case in T cell–deficient nude mice
(Supplementary Fig. S1C).
Preservation of CD80 expression on in vivo passage. If low
CD80 expression is considered as an advantageous feature in
immunocompetent hosts, its expression will likely be evolutionarily
preserved in tumor cells explanted from CT26 tumors growing
in immunocompetent mice. This was confirmed in experiments
shown in Supplementary Fig. S2, in which the relative intensity of
CD80-specific immunofluorescence in explanted tumor cells from
immunodeficient or immunocompetent mice is plotted referred to
CD80 level of expression on cultured CT26 (taken as 100%). It can
be seen that CD80 expression is preserved both in immunocom-
petent and immunodeficient Rag/ hosts even if they had been
depleted of natural killer cells. Again, this observation suggests that
low surface CD80 might have been selected for tumor escape from
immunity.
These findings are unlikely explained by clonal heterogeneous
expression of CD80 because in 18 randomly chosen limiting
dilution–derived CT26 clones, the means of CD80 fluorescence
intensity were almost identical, as illustrated by a coefficient of
variation (CV = SD/mean) inferior to 3% of the mean (data not
shown).
CD80-negative tumor cell lines are induced to express low
levels of CD80 on in vivo grafting, whereas successfully
grafted CD80high transfected tumor cells reduce, but do not
lose, CD80 expression. MC38 and B16OVA melanoma are
completely negative for CD80 immunostaining in tissue culture
Figure 5. CD80 silencing in CT26
cells abrogates tumorigenicity in
immunocompetent hosts. A, siRNA
sequences cloned in pSUPER to inhibit
CD80 expression. A scrambled sequence
with the same base composition in
different order was used as a control.
B, comparative analysis of tumor
progression (size follow-up and fraction of
mice completely rejecting their tumors) in
BALB/c and Rag-2/ syngenic mice
after a s.c. injection of 5  105 cells from
stable transfectants with a plasmid
encoding the siRNAs whose sequence is
specified in (A ) or a randomly scrambled
sequence of similar length and base
composition as a control. Levels of CD80
expression in the indicated stably
transfected clones are provided in the
accompanying histograms as well as the
level of CD80 in untransfected CT26
(CT26-WT). Data pooled from three
independent experiments with a total of
17 mice per group permitted a Fisher’s
exact test that showed a two-sided
P < 0.0001 when comparing rejection rates
of the silenced versus control (nonsilenced)
CT26 variants.
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but become positive in cell suspensions obtained from grafted
tumors in syngeneic mice (Fig. 6A and B). Electronic gating
and exclusion of CD45+ hematopoietic cells in the FACS analyses
ensured that the CD45-negative malignant cells were the only
ones analyzed in Fig. 6. Interestingly when these cells were
plated in culture for 7 days, a complete loss of surface CD80
took place.
As shown in Fig. 4C , the C51B7/10 CD80bright transfectant
grafted as a terminal tumor in only 50% of the cases. Explanted cell
suspensions of such tumors showed lower, but importantly not
negative, CD80 expression levels than the original transfected
cell line in culture (Fig. 6C). As a whole, these data provide
evolutionary evidence for a selective advantage of low but not
negative expression of CD80 on cancer cells.
Discussion
The main findings in this study are the unexpected basal and
spontaneous expression of CD80 in transplantable tumor cell lines
that are commonly used for experimental cancer immunotherapy
experiments, in addition to observations on the role of low CD80
expression as an immune evasion mechanism.
To the best of our knowledge, this is the first report showing
spontaneous CD80 expression in mouse tumor cells of epithelial
origin, but it should be considered that CD80 up-regulation has
been detected in mouse tumors treated with chemotherapy or
radiotherapy (54, 55). These reports suggest the inducibility of
CD80 under stress conditions. The costimulatory molecule 4-1BBL
has also been found to be spontaneously expressed in some tumor
cell lines (56), a finding that is also in contrast with the fact that
4-1BBL transfection to high levels of expression augments the
immunogenicity of various tumors (57, 58).
It is not possible to tell whether the original tumors were CD80+
or if it was an acquired event that took place during in vitro or
in vivo passage. Sequencing of the cDNA disclosed no mutation,
suggesting that the membrane glycoproteins were fully functional,
as confirmed by CT26 staining with CTLA-4Ig. Interestingly, we
found by Northern blot, RT-PCR, and sequencing, the coexistence
of two alternative splicing variants of cd80 mRNA, as occurring
in splenic cells stimulated with lipopolysaccharide or IFN-g and
in cultured dendritic cells used as positive controls. Accordingly,
it should not be expected that CD80 would function differently
on the colon cancer cells compared with professional antigen-
presenting cells. Indeed, the function of CD80 on antigen-
presenting cells seems to be dual and related to the level of
expression because CD80dim immature dendritic cells suppress
T cell immunity in a CD80-dependent fashion, whereas CD80bright
mature dendritic cells promote immunity under proper conditions
(22, 23, 25). Our results with dendritic cells are in agreement with
the view that the low levels of CD80 expression on immature
dendritic cells would bind inhibitory CTLA-4 with competitive
advantage to stimulatory CD28, as suggested by other authors with
functional data using bone marrow chimeras with defects in CD80
expression on dendritic cells (24, 25).
Figure 6. Dim CD80 expression is
induced in MC38 and B16-OVA during
in vivo passage, whereas low levels of
CD80 expression are selected on in vivo
passage of CD80-high transfectants. MC38
(A), B16-OVA (B), and C51B7/10 (C ) were
inoculated in the flank of syngeneic mice.
Tumors were explanted when they reached
an average diameter of 15 mm and cell
suspensions obtained by grinding minced
tumors. For FACS analysis, CD45-positive
cells were electronically gated and
excluded so histograms only reflect CD80
levels of CD45-negative cells satisfying the
FSC/SSC features of malignant cells.
Cell suspensions were cultured for 1 week
and CD80 expression reassessed. Each
histogram represents an independent
explanted tumor cell suspension.
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B7-1 (CD80) and B7-2 (CD86) expression on tumor cells has been
found to strongly raise the immunogenicity of transplantable cell
lines (3, 4). The transfection of B7-1 generates cells that can even
work as prophylactic or therapeutic vaccines against untransfected
tumors by means of eliciting a strong CTL response (1). Most of
these experiments were carried out with stable transfectants that
had been sorted and selected for expression of very high levels of
CD80 on every cell. Moreover, no detailed study has been published
on the dose dependency of CD80 levels of expression and tumor
immunogenicity, a factor that might prove crucial when consid-
ering that CD80 has two counter-receptors with dramatically
opposite effects on the immune response. CD28 enhances T cell
receptor–induced proliferation and activation of effector functions
(14, 15), whereas CTLA-4 ligation arrests T cell cycle progression
(59). Expression of CTLA-4 is only induced on activated cells with
low levels of membrane expression but exquisitely directed to the
area of T-cell engagement (11). Importantly, the inhibitory CTLA-4
receptor displays >100-fold higher avidity for CD80 than CD28 (9).
It is tantalizing to speculate that low levels of CD80 might confer,
by selective binding affinity for CTLA-4, some advantage to tumor
progression in immunocompetent mice. In fact, lymphocytes that
infiltrate tumors have an activated membrane phenotype and
therefore are susceptible to CTLA-4-mediated inhibition (data not
shown). The possibility that CD80 could be shielding CT26 tumor
cells as targets for the CTL effector phase has been explored in light
of the effects reported by Saudemont et al. (28) and the effects
also shown by Hirano et al. for B7-H1 (39). Although we did our
cytotoxicity experiments from 4 to 20 hours with anti-CT26–
specific CTL, no increase of specific lysis upon CD80 blockade,
neither by mAbs nor CTLA-4Ig, was observed (Supplementary
Fig. S3). However, the in vivo situation could be different and
therefore we cannot completely disregard such a mechanism in our
tumor model.
Alternatively, tumor CD80 might enhance the function of
regulatory T cells (60). We have done an extensive series of
experiments aimed at costimulating CD4+CD25+ Treg suppressor
function with CD80+ CT26 cells rendered negative results in our
investigation. However, this mechanism is not definitively ruled out
because Treg cells are known to express relatively high levels of
membrane CTLA-4 that paradoxically costimulates this population
(61, 62), and CT26 grafting is prevented by depleting CD25+
lymphocytes (63).
Another mechanistic possibility is that CD80 ligation by CTLA-4
on CT26 could provide advantageous signals to the tumor cell.
Although unlikely in epithelial cells, this possibility has been
observed in mouse dendritic cells in which CD80 engagement by
CTLA-4 promotes IFN-g secretion that in turn induces the immune
inhibitory enzyme indoleamine 2,3-dioxygenase (IDO; ref. 64). We
have explored this possibility in detail measuring IDO expression
at the RNA and protein level as well as the production of IDO
products without finding any involvement of CD80 cross-linking in
CT26 cells. Up-regulation of IDO expression and function occurred
following IFN-g stimulation, but was not further costimulated by
CD80 cross-linking in these cells (data not shown). Therefore, the
exact mechanism(s) behind the anti-immune advantage of low
CD80 expression on the malignant cell surface remains elusive as
is the case for the low CD80 expression on immature dendritic
cells (25).
Gene silencing with siRNA is a powerful tool used to examine the
role of a cellular protein. By these means, controlled selective
decrease of expression of a specific gene is achieved with minimal
residual expression (49). To generate stable transfectants, we used
two different constructs targeting distinct sequences of CD80 to
assure specificity. Selection of cloned CT26 variants that clearly
express much lower levels of CD80 showed that CD80 was not
absolutely required for grafting in animals devoid of a functional
immune system, but was necessary to avoid immune rejection. On
the other hand, CD80 levels on CT26 were only minimally reduced
after in vivo passage in BALB/c mice, even if compared with both B
cell– and T cell–deficient mice and to B cell–, T cell–, and natural
killer cell–deficient mice (Rag-2/ mice depleted of asialoGM-
1+cells; Supplementary Fig. S2). It can be concluded that, in vivo ,
the immune system exerts little or no pressure against low surface
CD80 whereas reducing, but not abolishing, CD80 expression in
successfully grafted CD80bright transfectants. Moreover, we clearly
show that CD80 is induced in vivo on the surface of malignant
cell lines that are negative during in vitro culture. We are currently
exploring the stimuli that could be involved in such in vivo regulation.
Importantly, CD80 and CD86 expression has been found in a
series cases of human melanoma in which low levels of RNA
expression have been frequently documented (40, 41). These
findings, precisely in a human malignancy characterized by a
certain degree of intrinsic immunogenicity, suggest that B7 family
molecules could be involved in subverting routes of immune
destruction of tumors. In fact, B7 molecules are more frequently
detected in those cases of melanoma with a higher number of
metastatic nodules (41). In addition, the expression of B7 molecules
in leukemia and myeloma cells is correlated with faster disease
progression (42, 43). The presence of CD80 in other human cell
lines or in tissue sections from human colorectal carcinomas is
currently under investigation.
Another molecule of the family, B7-H1, has been described to be
expressed on human and mouse tumor cells of various tissue
origins as observed both in cultured cell lines and in tissue sections
(38). By expression of B7-H1, human cancers may evade adaptative
immune responses by promoting the apoptosis of activated T cells
or by stimulating IL-10 production to deactivate T cells (65). B7-H1
does not bind CD28 or CTLA-4, but it binds PD-1, a T-cell surface
molecule also involved in the down-regulation of immune
responses (36, 38). It has been recently described that B7-H1
expression renders tumors resistant to immunotherapy and that
this effect could be reverted by blocking B7-H1 or PD-1 with
specific antibodies (39). The overall emerging picture is that B7
family members can be broadly exploited by tumor cells as a way
to escape immune destruction. In the particular case of CD80,
tumors cunningly exploit the dual function of this molecule by
expressing low surface levels, which preferentially engage its high-
avidity inhibitory T-cell ligand CTLA-4.
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